BUZZ0.430%
as of Jul 17
TGTX
GrowthTG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Close · 3M
+84.86%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals6
Win rate83% (5/6)
Avg buy return+6.60%
BUZZ · Weight decrease · 2d
TGTX is currently priced at $54.89, trading at 93% of its 52-week high of $59.06, following a substantial 30-day return of +46.7% and a 90-day return of +89.1%. This significant price run-up likely led to a shift in the positive-sentiment intensity detected by BUZZ’s NLP engine, which scans social media, blogs, and news. As the ETF primarily tracks retail-crowd signals, the consecutive weight decrease from 0.4600% to 0.4400% between July 10th and 13th suggests a tempering of public enthusiasm for TGTX following its swift ascent, rather than a lack of initial interest. The algorithmic tracker registered a decline in the stock's ranking based on positive sentiment, causing the gradual reduction in its portfolio allocation after a period of stability at higher weights.
weight 0.460% → 0.440% (-0.020 pp)·stock up 18.0% in the 30 days before
Jul 13·entry $55.01·now $53.96
-1.91%
since Jul 13
BUZZ · Weight increase · 2d
BUZZ’s methodology, which uses NLP to analyze social media and news for positive sentiment, responded to an increase in favorable discussion around TG Therapeutics. The fund, a passive algorithmic sentiment tracker, allocated a larger portion to TGTX, leading to its consecutive weight increase to 0.46% on July 7th. This adjustment aligns with the ETF’s monthly index reconstitution, reflecting heightened interest in the ~75 US large/mid caps it tracks. A significant factor contributing to this sentiment is TGTX’s recent price action, including a 30-day return of +44.0%, pushing the stock to 99% of its 52-week high.
weight 0.420% → 0.460% (+0.040 pp)·stock up 43.1% in the 30 days before
Jul 7·entry $58.06·now $53.96Fresh
-7.06%
since Jul 7
BUZZ · Weight decrease · 2d
TG Therapeutics, Inc. (TGTX) has seen its price climb significantly, posting a 30-day return of +35.7% and trading at $53.52, which is 96% of its 52-week high. Despite this sustained upward momentum, the BUZZ NextGen AI US Sentiment Leaders Index, which relies on NLP analysis of social media and news for positive-sentiment intensity, indicated a shift in its allocation criteria. The fund's weight in TGTX decreased consecutively from 0.44% on June 29th to 0.42% on June 30th. This adjustment suggests that as TGTX approached its 52-week peak, the intensity of positive sentiment among the retail-crowd signals monitored by BUZZ began to moderate, rather than indicating a fundamental decline in overall positivity.
weight 0.450% → 0.420% (-0.030 pp)·stock up 44.8% in the 30 days before
Jun 30·entry $54.94·now $53.96
-1.78%
since Jun 30
BUZZ · Weight increase · 3d
BUZZ, which tracks the BUZZ NextGen AI US Sentiment Leaders Index by ranking ~75 US large/mid cap stocks based on NLP analysis of social media and news, consistently raised its allocation to TG Therapeutics over three consecutive days. This algorithmic adjustment reflects a discernible build-up of positive retail-crowd signal around the Health Care company, a core input for the fund’s monthly rebalance. The sustained upward trend in weight, from 0.4100% to 0.4300% between June 22 and June 24, suggests increasing online endorsement as the stock price reached 99% of its 52-week high. Such a move aligns with the ETF's method of passively holding companies experiencing heightened positive online discourse, particularly after TG Therapeutics delivered a 90-day return of +84.5%.
weight 0.400% → 0.430% (+0.030 pp)·stock up 37.9% in the 30 days before
Jun 24·entry $53.60·now $53.96Fresh
+0.67%
since Jun 24
BUZZ · Weight increase · 2d
TG Therapeutics, Inc. (TGTX) currently trades at $53.60, positioned at 99% of its 52-week high, having delivered a 90-day return of +88.1% and a 30-day return of +26.0%. This upward price trajectory and proximity to its annual high align with the methodology of the BUZZ ETF, which tracks positive sentiment gathered from social media, news, and message boards using NLP. The fund's recent adjustments for TGTX, including increases from 0.4400% to 0.4500% on June 12th and 0.4500% to 0.4700% on June 17th, indicate a detection of intensifying positive public opinion around the health care company, reflecting its role as a retail-crowd signal among the funds tracked. Despite monthly index reconstitution, the observed pattern of consecutive daily weight increments, such as the 0.4000% to 0.4100% to 0.4200% sequence from June 18th to June 23rd, suggests the underlying NLP models continue to register a sustained, high-intensity positive sentiment for TGTX within its tracking universe, even at an elevated valuation.
weight 0.400% → 0.420% (+0.020 pp)·stock up 37.5% in the 30 days before
Jun 23·entry $53.94·now $53.96Fresh
+0.04%
since Jun 23
BUZZ · Accumulation · 5d
The weight of TGTX in the BUZZ portfolio exhibited a gradual accumulation, rising from 0.3600% to 0.4700% over ten trading days in June, even as the Health Care stock reached its 52-week high of $53.22. This measured increase reflects the sustained positive-sentiment intensity detected by BUZZ's NLP algorithms across social media and news sources. Given TGTX’s 90-day return of +82.6%, this consistent upward price momentum likely fueled a growing, distributed retail-crowd signal of optimism. BUZZ, as an algorithmic sentiment tracker rebalancing monthly, responded by steadily increasing its passive allocation to TGTX as the perceived positive sentiment strengthened and persisted through these price gains. This particular shape of accumulation directly aligns with the ETF's method of tracking and reacting to an enduring bullish narrative in the retail investment space.
weight 0.360% → 0.470% (+0.110 pp)·stock up 30.4% in the 30 days before
Jun 17·entry $51.50·now $53.96Drifting
+4.78%
since Jun 17
BUZZ · Weight increase · 2d
BUZZ, tracking the BUZZ NextGen AI US Sentiment Leaders Index, increased its allocation to TGTX primarily due to rising positive sentiment detected by its NLP algorithms across social media, blogs, and news. The algorithmic sentiment tracker, which passively holds around 75 US large/mid caps, captured a sustained and intensifying positive discussion around TGTX, leading to consecutive weight increases from 0.40% on June 9th to 0.44% on June 10th. This heightened sentiment directly reflects the company’s recent market performance, as TGTX currently trades at $48.05, representing 100% of its 52-week high, after achieving a +42.2% return over the last 30 days. The fund's monthly rebalancing mechanism would have integrated this sustained positive signal, signaling the crowd's favorable view.
weight 0.360% → 0.440% (+0.080 pp)·stock up 8.1% in the 30 days before
Jun 10·entry $46.62·now $53.96Chased
+15.74%
since Jun 10
BUZZ · Weight decrease · 3d
The weight for TG Therapeutics, Inc. (TGTX) in BUZZ exhibited a series of gradual, stepped decreases from 0.3700% down to 0.3100% over the specified period, with brief plateaus. This cadence reflects a subtle, sustained shift in the underlying positive-sentiment intensity tracked by BUZZ’s NLP analysis across social media and news sources. Despite TGTX’s current price of $37.41, sitting at 87% of its 52-week high following a 90-day return of +18.3%, the algorithmic sentiment tracker indicates a tempering of new enthusiastic discussions. As an ETF closely tracking retail-crowd signals, these incremental daily weight reductions suggest a plateauing of collective excitement, rather than a sharp negative turn, for a stock that has already performed strongly over the medium term. The ETF’s passive alignment with its monthly rebalancing index then translates these detected shifts in sentiment into the observed small, precise adjustments in TGTX's portfolio weight.
weight 0.350% → 0.310% (-0.040 pp)·stock up 13.0% in the 30 days before
May 29·entry $37.94·now $53.96
+42.22%
since May 29
BUZZ · Weight decrease · 2d
TGTX experienced a steady decrease in its weight within the BUZZ portfolio, moving from 0.3500% to 0.3300% between May 26th and May 28th, following a period of stability. This subtle, daily tapering of exposure is consistent with BUZZ's strategy as an algorithmic sentiment tracker, which uses NLP over social media, blogs, and news to rank stocks by positive-sentiment intensity. As TGTX trades at $37.94, representing 88% of its 52-week high and having achieved a +20.2% return over 90 days, the fund's underlying index likely detected a slight reduction in the *intensity* of positive public commentary surrounding the health care company, rather than an emergence of negative sentiment. The index’s mechanism, focusing on a broad aggregation of retail-crowd signals for positive discussion, would naturally adjust holdings in fractional steps as the collective enthusiasm for the stock marginally subsided from its prior fervor.
weight 0.350% → 0.330% (-0.020 pp)·stock up 12.3% in the 30 days before
May 28·entry $38.82·now $53.96
+39.00%
since May 28
BUZZ · Weight decrease · 2d
The weight history for TGTX in BUZZ reveals a cadence of stepped reductions, most recently seen with consecutive daily decreases from 0.37% on May 19 to 0.35% by May 21. This gradual erosion of weight, instead of an abrupt change, aligns with VanEck's BUZZ ETF, which tracks sentiment via NLP over social media and news and rebalances its portfolio monthly. Despite TG Therapeutics trading at $38.87, near 90% of its 52-week high after a 15.0% 30-day return, the underlying sentiment intensity detected by the index appears to be softening. This measured adjustment indicates that while the stock has performed well, the positive retail-crowd signal driving BUZZ's ~75 US large/mid cap holdings has slightly diminished for TGTX.
weight 0.370% → 0.350% (-0.020 pp)·stock up 2.4% in the 30 days before
May 21·entry $39.24·now $53.96
+37.51%
since May 21
BUZZ · Weight increase · 2d
The AI-managed ETF likely increased its TGTX allocation due to detecting a significant positive catalyst, such as favorable clinical trial results or regulatory approval, indicating growing conviction. This consecutive weight increase suggests the AI is reacting to reinforcing positive signals in the market. For retail investors, this serves as an alert to investigate TGTX further for the specific news or fundamental changes the AI identified, rather than a direct buy recommendation. Always conduct independent research and assess the investment against your own financial goals and risk tolerance.
weight 0.340% → 0.400% (+0.060 pp)·stock up 25.8% in the 30 days before
May 7·entry $43.02·now $53.96Chased
+25.42%
since May 7
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.